Fibroblast growth factor 21, fibroblast growth factor receptor 1, and β-Klotho expression in bovine growth hormone transgenic and growth hormone receptor knockout mice. (October 2016)

• Record Type: Journal Article
• Authors: Brooks, Nicole E.; Hjortebjerg, Rikke; Henry, Brooke E.; List, Edward O.; Kopchick, John J.; Berryman, Darlene E.
• Is Part Of: Growth hormone & IGF research. Volume 30/31(2016)
• Page Start: 22
• Page End: 30
• Publication Date: 2016-10
• Subjects: Fibroblast growth factor 21 -- FGF21 -- Fibroblast growth factor receptor 1 -- FGFR1 -- β-klotho -- KLB -- bGH mice -- GHR −/− mice; Growth regulators -- Periodicals; Growth -- Regulation -- Periodicals; Somatomedin -- Periodicals; Somatomedins -- Periodicals; Growth Hormone -- Periodicals; Growth Substances -- Periodicals; Croissance -- Régulation -- Périodiques; Croissance -- Régulateurs -- Périodiques; Somatotrophine -- Périodiques; Somatomédine -- Périodiques; Growth -- Regulation; Growth regulators; Electronic journals; Periodicals; Electronic journals; 612.4
• DOI: 10.1016/j.ghir.2016.08.003
• Languages: English
• ISSNs: 1096-6374

Abstract

Abstract: Objective: Although growth hormone (GH) and fibroblast growth factor 21 (FGF21) have a reported relationship, FGF21 and its receptor, fibroblast growth factor receptor 1 (FGFR1) and cofactor β-Klotho (KLB), have not been analyzed in chronic states of altered GH action. The objective of this study was to quantify circulating FGF21 and tissue specific expression of Fgf21, Fgfr1, and Klb in mice with modified GH action. Based on previous studies, we hypothesized that bovine GH transgenic (bGH) mice will be FGF21 resistant and GH receptor knockout (GHR −/−) mice will have normal FGF21 action. Design: Seven-month-old male bGH mice ( n = 9) and wild type (WT) controls ( n = 10), and GHR −/− mice ( n = 8) and WT controls (n = 8) were used for all measurements. Body composition was determined before dissection, and tissue weights were measured at the time of dissection. Serum FGF21 levels were evaluated by ELISA. Expression of Fgf21, Fgfr1, and Klb mRNA in white adipose tissue (AT), brown AT, and liver were evaluated by reverse transcription quantitative PCR. Results: As expected, bGH mice had increased body weight ( p = 3.70E − 8 ) but decreased percent fat mass ( p = 4.87E − 4 ). Likewise, GHR −/− mice had decreased body weight ( p = 1.78E − 10 ) but increased percent fat mass ( p = 1.52E − 9 ), due to increased size of the subcutaneous AT depot when normalized to body weight ( p = 1.60E − 10 ). Serum FGF21 levels were significantly elevated in bGH mice ( p = 0.041) and unchanged in GHR −/− mice ( p = 0.88). Expression of Fgf21, Fgfr1, and Klb mRNA in white AT and liver were downregulated or unchanged in both bGH and GHR −/− mice. The only exception was Fgf21 expression in brown AT of GHR −/−, which trended toward increased expression ( p = 0.075). Conclusions: In accordance with our hypothesis, we provide evidence that circulating FGF21 is increased in bGH animals, but remains unchanged in GHR −/− mice. Downregulation or no change in Fgf21, Fgfr1, and Klb expression are seen in white AT, brown AT, and liver of bGH and GHR −/− mice when compared to their respective controls, except for an increase in brown AT Fgf21 expression in GHR −/− mice, which could suggest a possible link to increased thermogenic potential in these mice. Overall, these results suggest possible modulation of FGF21 by GH resulting in FGF21 resistance or changes in FGF21 levels due to GH induced changes in liver size or kidney function. Highlights: Serum FGF21 is elevated in male bGH mice and unchanged in male GHR −/− mice. mRNA levels of Fgf21, Fgfr1, and Klb are downregulated or unchanged in these mice. Suggests GH-induced modulation of FGF21 expression FGF21 changes possibly explained by FGF21 resistance, liver size, or renal function